Preliminary results from the US Food and Drug Administration's (FDA's) mandated postmarket surveillance studies of duodenoscopes show "higher-than-expected" contamination rates after reprocessing, according to an article on the Medscape website.
The FDA said 3 percent of properly collected samples tested positive for more than 100 colony-forming units of "low-concern" organisms.
These organism are unlikely to cause serious infections but are, nevertheless, an indication of a "reprocessing failure."
An additional 3 percent of properly collected samples tested positive for "high-concern" bacteria that are more often associated with disease.
Backup Power Is a Lifeline: What Healthcare Facility Managers Must Get Right
3 Pillars of Stronger Cybersecurity in Healthcare
Piedmont Fayette Hospital to Build New Patient Tower
Texas HHSC Announces Construction of New Lubbock Psychiatric Center
Armed Standoff at West Virginia Hospital Reminds of the Need for Safety Measures